The Janus kinase inhibitor baricitinib, in combination with narrowband ultraviolet B therapy, improved vitiligo, according to ...

If you’re under age 12, we don’t have any drug that is specifically indicated,” Dr. Lawrence F. Eichenfield said.

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes ...

Janus kinase (JAK) inhibitors are relatively new in the treatment ... This is especially true with the oral versions of the medication. Rare but serious complications may include: heart attack ...

The primary outcome of the study was the attainment of low disease activity at week 12, defined as a C-reactive protein (CRP) polymyalgia rheumatica activity score (PMR-AS) of 10 or less without oral ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by Novartis to study ...

Limited clinical data is available advocating the use of jak-inhibitors as an effective treatment for autoimmune complications of PTPN2-deficiency. However, the mechanism of pathogenesis for these ...

JAK inhibitors have since emerged as a promising ... et al "Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort ...

The carbonic anhydrase inhibitor, Diamox, was employed as a diuretic for oral administration in 26 patients with congestive heart failure. Diamox prevented the secretion of an acid urine and ...